Analysts Set Expectations for SLNO FY2025 Earnings

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Equities research analysts at Cantor Fitzgerald decreased their FY2025 EPS estimates for shares of Soleno Therapeutics in a research note issued on Tuesday, March 4th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will earn ($2.65) per share for the year, down from their previous forecast of ($1.97). The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share.

Soleno Therapeutics (NASDAQ:SLNO) last released its earnings results on Wednesday, March 5th. The company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.41).

A number of other research analysts also recently issued reports on SLNO. Stifel Nicolaus initiated coverage on shares of Soleno Therapeutics in a research note on Wednesday. They issued a “buy” rating and a $74.00 price target for the company. Lifesci Capital raised shares of Soleno Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 4th. Robert W. Baird reissued an “outperform” rating and issued a $72.00 target price on shares of Soleno Therapeutics in a report on Monday, December 2nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $70.00 price objective on shares of Soleno Therapeutics in a research report on Monday. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Soleno Therapeutics currently has a consensus rating of “Buy” and an average target price of $71.20.

Soleno Therapeutics Stock Performance

Shares of Soleno Therapeutics stock opened at $44.99 on Thursday. The business has a 50-day simple moving average of $47.20 and a 200-day simple moving average of $49.86. Soleno Therapeutics has a one year low of $36.61 and a one year high of $60.92. The company has a market cap of $1.94 billion, a PE ratio of -13.55 and a beta of -1.46.

Insider Buying and Selling at Soleno Therapeutics

In other Soleno Therapeutics news, CFO James H. Mackaness sold 4,083 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $45.41, for a total value of $185,409.03. Following the transaction, the chief financial officer now directly owns 115,089 shares of the company’s stock, valued at approximately $5,226,191.49. The trade was a 3.43 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Bhatnagar Anish sold 10,937 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $45.41, for a total transaction of $496,649.17. Following the completion of the sale, the chief executive officer now owns 708,616 shares of the company’s stock, valued at $32,178,252.56. This trade represents a 1.52 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 17,360 shares of company stock valued at $790,119 in the last ninety days. Insiders own 12.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. AlphaQuest LLC raised its stake in shares of Soleno Therapeutics by 1,154.4% during the 4th quarter. AlphaQuest LLC now owns 715 shares of the company’s stock worth $32,000 after buying an additional 658 shares in the last quarter. US Bancorp DE purchased a new stake in shares of Soleno Therapeutics during the 4th quarter worth approximately $34,000. Avanza Fonder AB purchased a new stake in shares of Soleno Therapeutics in the 4th quarter worth about $76,000. Springhill Fund Asset Management HK Co Ltd acquired a new stake in shares of Soleno Therapeutics in the fourth quarter valued at approximately $81,000. Finally, Avior Wealth Management LLC acquired a new position in shares of Soleno Therapeutics during the 4th quarter worth approximately $89,000. 97.42% of the stock is currently owned by institutional investors and hedge funds.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.